Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML. Weisel K, et al. Pharmacol Res Perspect. 2017 Dec;5(6):e00365. doi: 10.1002/prp2.365. Pharmacol Res Perspect. 2017. PMID: 29226626 Free PMC article. Clinical Trial.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Sandborn WJ, et al. Among authors: weisel k. Gastroenterology. 2022 May;162(6):1650-1664.e8. doi: 10.1053/j.gastro.2022.01.047. Epub 2022 Feb 5. Gastroenterology. 2022. PMID: 35134323 Free article. Clinical Trial.
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.
Ahmadi P, Alsdorf W, Leypoldt L, Kosch R, Schaefers C, Gagelmann N, Ayuk F, Kron F, Weisel K. Ahmadi P, et al. Among authors: weisel k. Bone Marrow Transplant. 2025 Jan 22. doi: 10.1038/s41409-024-02505-x. Online ahead of print. Bone Marrow Transplant. 2025. PMID: 39843583 No abstract available.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Moreau P, et al. Among authors: weisel k. Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02506-1. Online ahead of print. Leukemia. 2025. PMID: 39815052
Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial.
Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Sauer S, Merz M, Mai EK, Müller-Tidow C, Luntz S, Jauch A, Brossart P, Goerner M, Klein S, Glass B, Reimer P, Graeven U, Fenk R, Haenel M, von Metzler I, Lindemann HW, Scheid C, Blau IW, Salwender HJ, Noppeney R, Besemer B, Weisel KC, Goldschmidt H. Baertsch MA, et al. Among authors: weisel kc. Blood. 2025 Jan 14:blood.2024027342. doi: 10.1182/blood.2024027342. Online ahead of print. Blood. 2025. PMID: 39808798
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.
Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M. Richardson P, et al. Among authors: weisel k. Eur J Haematol. 2025 Jan 8. doi: 10.1111/ejh.14365. Online ahead of print. Eur J Haematol. 2025. PMID: 39777934
314 results